Nanjing Pharmaceutical released its 2026 interim report. Total operating revenue was 27.823 billion yuan, and net profit attributable to the parent company was 294 million yuan, an increase of 3.1945 million yuan from the same period last year, up 1.10% year on year. Net cash flow from operating activities was negative 5.160 billion yuan. The asset-liability ratio was 77.14%, and the gross margin was 6.03%, up 0.11 percentage points from the same period last year. Diluted earnings per share were 0.23 yuan, up 3.15% year on year. The number of shareholders was 53,000, and the top ten shareholders held 61.46% of the total share capital.
NanJing Pharmaceutical Co LtdNet profit increased 1.10% year on year, with diluted EPS up 3.15%.
